Search results for "Adrenergic beta-2 Receptor Antagonists"

showing 5 items of 5 documents

Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants

2014

Acute bronchiolitis is the leading cause of lower respiratory t ract infection and hospitalization in children less than 1y ear of age worldwide. It is usually a mild disease, but some children may develop severe symptoms, requiring hospital admission and ventilatory support in the ICU. Infants with pre-existing risk factors (prematurity, bronchopulmonary dysplasia, congenital heart diseases and immunodeficiency) may be predisposed to a severe form of the disease. Clinical diagnosis of bronchiolitis is manly based on medical history and physical examination (rhinorrhea, cough, crackles, wheezing and signs of respiratory distress). Etiological diagnosis, with antigen or genome detection to i…

PediatricsBronchiolitis; Bronchopulmonary dysplasia; Congenital heart diseases; Immunodeficiency; Oxygen therapy; Prematurity; Prevention; Prophylaxis; Respiratory syncytial virus;ReviewRespiratory syncytial virusSeverity of Illness IndexCongenital heart diseasesSettore MED/38 - Pediatria Generale E SpecialisticaAdrenergic beta-2 Receptor AntagonistsVitamin DChildrenRespiratory distressVitaminsEnvironmental exposurePatient DischargeAnti-Bacterial AgentsBronchodilator AgentsHospitalizationSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICABronchiolitisbronchiolitisPrematuritymedicine.drugPalivizumabRespiratory Therapymedicine.medical_specialtyEpinephrineDecision MakingAntibodies Monoclonal HumanizedAntiviral AgentsIntensive Care Units NeonatalBronchiolitis Respiratory syncytial virus Prematurity Bronchopulmonary dysplasia Congenital heart diseases Immunodeficiency Oxygen therapy Prevention ProphylaxismedicineHumansImmunodeficiencyAcute bronchiolitisMedical historyConsensus DocumentIntensive care medicineGlucocorticoidsPalivizumabAsthmaSaline Solution HypertonicPrimary Health CareProphylaxisbusiness.industryNebulizers and VaporizersPreventionInfant NewbornOxygen Inhalation TherapyHumidityEnvironmental ExposureAcute bronchiolitis Consensus Documentmedicine.diseaseBronchopulmonary dysplasiaOxygen therapyHypertonic salineBronchopulmonary dysplasiaBronchiolitisbusinessItalian Journal of Pediatrics
researchProduct

How pediatricians in Spain manage the first acute wheezing episode in an atopic infant. Results from the TRAP study.

2005

Abstract Background Although the treatment of asthma has been addressed in several guidelines, the management of the first acute wheezing episode in infants has not often been evaluated. We surveyed practicing pediatricians in Spain about the treatment they would provide in a simulated case. Material and methods A random sample of 3000 pediatricians and physicians who normally treated children was surveyed. The questionnaire inquired about how they would treat a first mild-to-moderate wheezing attack in a 5-month-old boy with a personal and family history of allergy. Pediatricians were asked about their professional background. Results A total of 2347 questionnaires were returned with usefu…

Pulmonary and Respiratory MedicineHypersensitivity ImmediateAllergyPediatricsmedicine.medical_specialtyImmunologyAdrenergic beta-AntagonistsAdministration OralPrimary carePediatricsMaintenance therapyAdrenal Cortex HormonesAdrenergic beta-2 Receptor AntagonistsRecurrenceSurveys and QuestionnairesAdministration InhalationmedicineImmunology and AllergyHumansRespiratory soundsAnti-Asthmatic AgentsMetered Dose InhalersFamily historyPractice Patterns Physicians'AsthmaRespiratory Soundsmedicine.diagnostic_testBronchial Spasmbusiness.industryInhalerData CollectionMasksInfantGeneral Medicinemedicine.diseaseAsthmaSpainChild PreschoolOral steroidAcute DiseasePractice Guidelines as TopicDrug Therapy CombinationGuideline AdherencebusinessCase ManagementInhalation SpacersAllergologia et immunopathologia
researchProduct

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

2011

Two, once daily (q.d.) inhaled bronchodilators are available for the treatment of chronic obstructive pulmonary disease (COPD): the β(2)-agonist indacaterol and the anticholinergic tiotropium. This blinded study compared the efficacy of these two agents and assessed their safety and tolerability. Patients with moderate-to-severe COPD were randomised to treatment with indacaterol 150 μg q.d. (n=797) or tiotropium 18 μg q.d. (n=801) for 12 weeks. After 12 weeks, the two treatments had similar overall effects on "trough" (24 h post-dose) forced expiratory volume in 1 s. Indacaterol-treated patients had greater improvements in transition dyspnoea index (TDI) total score (least squares means 2.0…

Pulmonary and Respiratory MedicineSpirometryMalemedicine.drug_classScopolamine DerivativesQuinolonesSeverity of Illness IndexCholinergic AntagonistsDrug Administration ScheduleMedical Recordslaw.inventionPulmonary Disease Chronic ObstructiveRandomized controlled trialDouble-Blind MethodlawAdrenergic beta-2 Receptor AntagonistsForced Expiratory VolumemedicineAnticholinergicHumansTiotropium BromideAdverse effectAgedCOPDmedicine.diagnostic_testbusiness.industryTiotropium bromideMiddle Agedmedicine.diseaserespiratory tract diseasesBronchodilator AgentsTreatment OutcomeTolerabilitySpirometryAnesthesiaIndansIndacaterolFemalebusinessmedicine.drugThe European respiratory journal
researchProduct

Impact of long-term treatment with inhaled corticosteroids and bronchodilators on lung function in a patient with post-infectious bronchiolitis oblit…

2016

Post-infectious bronchiolitis obliterans (PIBO) is a small airways disease characterized by fixed airflow limitation. Therefore, inhaled bronchodilators and corticosteroids are not recommended as maintenance therapy options. The management of PIBO currently consists only of close monitoring of affected patients, aimed at the prevention and early treatment of pulmonary infections. In recent years, there has been an increase in the incidence of PIBO in the pediatric population. Patients with PIBO are characterized by a progressive decline in lung function, accompanied by a decrease in overall functional capacity. Here, we report the case of a relatively young man diagnosed with PIBO and follo…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyLong term treatmentmedicine.drug_classmedicine.medical_treatmentBronchiolitis obliteransInhaled corticosteroidsAnti-inflammatory agents/ therapeutic useCase ReportMuscarinic antagonists/therapeutic use03 medical and health sciences0302 clinical medicineAnti-inflammatory agents/therapeutic useBronchodilatormedicinePulmonary rehabilitation030212 general & internal medicineBronchiolitis obliterans/therapyLung functionGynecologylcsh:RC705-779Administration inhalationinhalationbusiness.industrylcsh:Diseases of the respiratory systemmedicine.diseaseAdministration inhalation; Adrenergic beta-2 receptor antagonists/therapeutic use; Anti-inflammatory agents/ therapeutic use; Bronchiolitis obliterans/therapy; Infection/complications; Lung diseases/rehabilitation; Muscarinic antagonists/therapeutic use; Pulmonary and Respiratory MedicineLung diseases/rehabilitation030228 respiratory systemPhysical performanceInfection/complicationAnesthesiaInfection/complicationsAdministrationbusinessAdrenergic beta-2 receptor antagonists/therapeutic usePediatric populationJornal Brasileiro de Pneumologia
researchProduct

What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis

2020

Abstract Background The choice of inhaler device for asthma patients depends upon multiple attributes. We investigated factors that may drive general practitioners (GPs) and respiratory specialists in the prescription of inhaler devices for asthma patients who initiated inhalation therapy. Methods We retrospectively analysed prescriptions by GPs and respiratory specialists to asthma patients commencing inhaled corticosteroid/long-acting β2-agonist combination therapy available as both pressurised metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs). Patient characteristics were compared by device and multivariate analysis was used to model the likelihood of receiving a pMDI as oppos…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyMultivariate analysisSettore MED/10 - Malattie Dell'Apparato RespiratorioGeneral practitioner03 medical and health sciencesdry powder inhaler0302 clinical medicineInhalersAdrenal Cortex HormonesAdrenergic beta-2 Receptor AntagonistsAsthma controlGeneral practitionersAdministration InhalationRetrospective analysisMedicine030212 general & internal medicineMetered Dose InhalersMedical prescriptionAsthmaRetrospective Studiesbusiness.industryInhalerdry powder inhalersInhalerOdds ratiomedicine.diseaseConfidence intervalAsthmaPressurised metered-dose inhalerAsthma; dry powder inhalers; General practitioners; Inhalers; Pressurised metered-dose inhalers; Respiratory specialistsPrescriptions030228 respiratory systemRespiratory specialistsInhalationDelayed-Action PreparationsEmergency medicineAdministrationPressurised metered-dose inhalersbusinessAsthma; dry powder inhalers; General practitioners; Inhalers; Pressurised metered-dose inhalers; Respiratory specialists; Administration Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Antagonists; Asthma; Delayed-Action Preparations; Retrospective Studies; Dry Powder Inhalers; Metered Dose Inhalers; Prescriptions
researchProduct